Department of Computational Biology, Indraprastha Institute of Information Technology, Okhla Phase 3, New Delhi 110020, India.
Cancer and Data Science Laboratory (CDSL), National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Drug Discov Today. 2024 Jul;29(7):104047. doi: 10.1016/j.drudis.2024.104047. Epub 2024 Jun 1.
During the past 20 years, there has been a significant increase in the number of protein-based drugs approved by the US Food and Drug Administration (FDA). This paper presents THPdb2, an updated version of the THPdb database, which holds information about all types of protein-based drugs, including peptides, antibodies, and biosimilar proteins. THPdb2 contains a total of 6,385 entries, providing comprehensive information about 894 FDA-approved therapeutic proteins, including 354 monoclonal antibodies and 85 peptides or polypeptides. Each entry includes the name of therapeutic molecule, the amino acid sequence, physical and chemical properties, and route of drug administration. The therapeutic molecules that are included in the database target a wide range of biological molecules, such as receptors, factors, and proteins, and have been approved for the treatment of various diseases, including cancers, infectious diseases, and immune disorders.
在过去的 20 年里，美国食品和药物管理局（FDA）批准的基于蛋白质的药物数量显著增加。本文介绍了 THPdb2，这是 THPdb 数据库的更新版本，其中包含有关所有类型的基于蛋白质的药物的信息，包括肽、抗体和生物类似蛋白。THPdb2 共包含 6385 条记录，提供了 894 种 FDA 批准的治疗性蛋白的全面信息，包括 354 种单克隆抗体和 85 种肽或多肽。每个条目都包含治疗分子的名称、氨基酸序列、物理化学性质和药物给药途径。数据库中包含的治疗分子针对广泛的生物分子，如受体、因子和蛋白质，并已批准用于治疗各种疾病，包括癌症、传染病和免疫紊乱。
